High Free Cash Flow Stocks
GMAB is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
GENMAB A/S -SP ADR (GMAB) Stock Price & Overview
NASDAQ:GMAB • US3723032062
Current stock price
26.45 USD
-0.07 (-0.26%)
At close:
26.45 USD
0 (0%)
After Hours:
The current stock price of GMAB is 26.45 USD. Today GMAB is down by -0.26%. In the past month the price decreased by -3.82%. In the past year, price increased by 23.14%.
GMAB Key Statistics
52-Week Range18.885 - 35.43
Current GMAB stock price positioned within its 52-week range.
1-Month Range25.72 - 29.43
Current GMAB stock price positioned within its 1-month range.
- Market Cap
- 16.238B
- P/E
- 15.11
- Fwd P/E
- 20.90
- EPS (TTM)
- 1.75
- Dividend Yield
- N/A
GMAB Stock Performance
Today
-0.26%
1 Week
-1.56%
1 Month
-3.82%
3 Months
-18.94%
Longer-term
6 Months -7.55%
1 Year +23.14%
2 Years -6.21%
3 Years -32.54%
5 Years -34.88%
10 Years N/A
GMAB Stock Chart
GMAB Stock Screens
GMAB currently appears in the following ChartMill screener lists.
GMAB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB turns out to be only a medium performer in the overall market: it outperformed 43.69% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GMAB. While GMAB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GMAB Earnings
On February 18, 2026 GMAB reported an EPS of 0.22 and a revenue of 1.06B. The company missed EPS expectations (-39.11% surprise) and beat revenue expectations (0.19% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 18, 2026
PeriodQ4 / 2025
EPS Reported$0.22
Revenue Reported1.058B
EPS Surprise -39.11%
Revenue Surprise 0.19%
GMAB Forecast & Estimates
27 analysts have analysed GMAB and the average price target is 36.06 USD. This implies a price increase of 36.34% is expected in the next year compared to the current price of 26.45.
For the next year, analysts expect an EPS growth of -27.83% and a revenue growth 18.39% for GMAB
Analysts
Analysts74.07
Price Target36.06 (36.33%)
EPS Next Y-27.83%
Revenue Next Year18.39%
GMAB Financial Highlights
Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 1.75. The EPS decreased by -2.61% compared to the year before.
Income Statements
Revenue(TTM)3.72B
Net Income(TTM)963.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.89% | ||
| ROA | 7.48% | ||
| ROE | 16.47% | ||
| Debt/Equity | 0.88 |
Chartmill High Growth Momentum
EPS Q2Q%-75.02%
Sales Q2Q%14.88%
EPS 1Y (TTM)-2.61%
Revenue 1Y (TTM)19.25%
GMAB Ownership
Ownership
Inst Owners43.37%
Shares613.91M
Float588.88M
Ins OwnersN/A
Short Float %1.35%
Short Ratio4.66
GMAB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GMAB
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
IPO: 2000-10-01
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
Valby 1560 DK
CEO: Jan G. J. van de Winkel
Employees: 3029
Phone: 4570202728
GENMAB A/S -SP ADR / GMAB FAQ
What does GENMAB A/S -SP ADR do?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
What is the current price of GMAB stock?
The current stock price of GMAB is 26.45 USD. The price decreased by -0.26% in the last trading session.
Does GMAB stock pay dividends?
GMAB does not pay a dividend.
What is the ChartMill technical and fundamental rating of GMAB stock?
GMAB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the ownership structure of GENMAB A/S -SP ADR (GMAB)?
You can find the ownership structure of GENMAB A/S -SP ADR (GMAB) on the Ownership tab.
What is the Short Interest ratio of GENMAB A/S -SP ADR (GMAB) stock?
The outstanding short interest for GENMAB A/S -SP ADR (GMAB) is 1.35% of its float.